PharmaCyte (PMCB) Director Robert Weinstein Cancels Erroneous Award

What Happened

• Robert Weinstein, a director of PharmaCyte Biotech, filed an amended Form 4 reporting an "other acquisition or disposition" (code J) dated 2026-03-31. The entry shows 0 shares at N/A and no dollar value. A footnote explains the reported grant was made in error and has been cancelled. No shares were acquired or transferred and there is no change in economic exposure from this entry.

Key Details

• Transaction date: 2026-03-31 (amended Form 4 filed 2026-07-17)
• Reported transaction: 0 shares, price N/A, total value N/A (derivative entry)
• Shares owned after transaction: no change (grant cancelled)
• Footnote: F1 — "The reported grant was made in error and has been cancelled."
• Filing status: this is an amended filing; it corrects the earlier report by cancelling the erroneous grant

Context

• This was not a purchase, sale, or exercise that changes insider holdings—it's a correction canceling an erroneously reported award. Such amendments clarify reporting records but do not indicate a change in insider sentiment or trading.